Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib with Chemoradiotherapy and Immunotherapy in Esophageal Cancer
NCT06569459Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jul 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of trilaciclib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence of grade >=3 neutropenia up to 84 days. Started Jul 2024; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06569459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06569459.